About NovalGen

NovalGen is a clinical stage biotechnology company developing breakthrough multi-specific biologics that transform outcomes for patients with cancer, autoimmune disorders, and blood diseases. Using its proprietary AutoRegulation platform technology, the company creates immunotherapies with built in self-regulating capabilities that maintain efficacy while preventing toxicities. Founded in 2019 and based on innovation from UCL, NovalGen builds strategic partnerships between academia and industry to advance its pipeline through clinical trials. The company has dosed its first patient in a Phase 1 trial for NVG-222, a first in class T cell engager, marking a milestone in delivering safer therapies that address unmet medical needs.